Am J Transplant, Volume 21, Suppl 3 Archives - Page 16 of 139 - ATC Abstracts

2021 American Transplant Congress
Single Incision Simultaneous Liver Kidney Transplantation: Outcomes and Feasibility
D. Imai, Y. Sambommatsu, A. Khan, S. Lee, A. Sharma, V. Kumaran, D. Bruno, A. Cotterell, C. Bhati, M. F. Levy
Virginia Commonwealth University, Richmond, VA
*Purpose: Simultaneous liver and kidney transplantation (SLK) is indicated in patients with concomitant end stage liver disease and severe chronic kidney disease or end stage…
2021 American Transplant Congress
Early Experience with Broad Renal Genetic Testing in an Academic Transplant Center
E. Tantisattamo¹, K. Brossart², N. Ioannou², S. McCormick², P. R. Billings², H. Tabriziani²
¹Division of Nephrology, Hypertension and Kidney Transplantation, Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, CA, ²Natera, Inc., San Carlos, CA
*Purpose: Genetic testing is an emerging tool in kidney transplantation (KT), particularly to assess risk of recurrent disease in patients with KT and for selection…
2021 American Transplant Congress
Treatment of Bk Virus With Intravenous Immunoglobulin in Pediatric Kidney Transplant
D. Mohammad, D. Kim, R. Baracco, G. Kapur, A. Jain
Pediatric Nephrology and Transplant Services, Children's Hospital of Michigan, Detroit, MI
*Purpose: To study the prevalence of BK viremia (BKV) and BK Virus Nephropathy (BKVN) utilizing plasma BK quantitative Polymerase Chain Reaction (qPCR) and report outcomes…
2021 American Transplant Congress
Donor Derived Cell-free DNA Kinetics Early After Kidney Transplant in Patients with Delayed Graft Function Who Received Kidneys from Donation After Cardiac Death Donors
R. Gumber, M. Abuzeineh, C. Mejia, D. Brennan, F. Naqvi
Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Delayed graft function (DGF) may reduce long-term kidney allograft survival due to ischemia-reperfusion injury and rejection. Donor Derived Cell-Free DNA (dd-cfDNA) is proposed to…
2021 American Transplant Congress
Treatment of Refractory Chronic Active Antibody-Mediated Rejection: Improvement in Histopathology are Delayed Compared to the Reduction in Donor Specific Antibodies
K. R. Degner¹, S. Parajuli¹, F. Aziz¹, N. Garg¹, M. Mohamed¹, D. A. Mandelbrot¹, S. E. Panzer¹, L. Hidalgo¹, N. A. Wilson¹, S. R. Reese¹, K. Van Hyfte¹, W. Zhong¹, P. Nickerson², A. Djamali¹
¹University of Wisconsin, Madison, WI, ²University of Manitoba, Winnipeg, MB, Canada
*Purpose: There are limited options for the treatment and management of refractory chronic active antibody-mediated rejection (cABMR) after kidney transplantation. Longitudinal histologic data in patients…
2021 American Transplant Congress
Donor-Derived Cell-Free DNA as a Surrogate Marker for “Allograft Quiescence” After Kidney Transplantation
J. S. Bromberg¹, L. Bu², G. Gupta³, I. Moinuddin³, S. Anand⁴, A. Pai⁵, T. Alhamad⁶, V. Bowers⁷, S. Ghosh⁸, W. Tian⁸, E. Stites⁹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Minnesota, Minneapolis, MN, ³Virginia Commonwealth University, Richmond, VA, ⁴Intermountain Medical Center, Murray, UT, ⁵University of Texas McGovern Medical School, Houston, TX, ⁶Washington University in St. Louis, St. Louis, MO, ⁷Tampa General Hospital, Tampa, FL, ⁸CareDx, Brisbane, CA, ⁹University of Colorado, Aurora, CO
*Purpose: Donor-derived cell-free DNA (dd-cfDNA; AlloSure®) and the association with active rejection (AR) was described by Bloom et al, however subsequent insights have suggested this…
2021 American Transplant Congress
Impact of Social Support, Social Circumstances and Distance from Transplant Center on Post Liver Transplant Outcomes: An Analysis from a Predominantly Rural U.S. Cohort
R. Kaur¹, C. Lavender¹, E. Askew¹, S. Jafri², R. Thandassery¹, M. Deneke¹
¹University of Arkansas for Medical Sciences, Little Rock, AR, ²Henry Ford Hospital, Detroit, MI
*Purpose: Social support and social circumstances (SSSC) are critical yet less described entities in post-orthotopic liver transplant (OLT). We aimed to describe SSSC and correlate…
2021 American Transplant Congress
Identification of Molecular Markers for Liver Cirrhosis by Single-nucleus Rna Sequencing
C. Kuscu¹, C. Kuscu¹, M. Akram², A. Shetty³, D. G. Maluf⁴, J. Eason¹, V. Mas⁵
¹Surgery, James D Eason Transplat Institute, Memphis, TN, ²Surgery, Center for Biomedical Informatics, Memphis, TN, ³Surgery, Institute for Genome Sciences, School of Medicine, Baltimore, MD, ⁴Surgery, Program in Transplantation University of Maryland, Baltimore, MD, ⁵Surgery, Division of Surgical Science University of Maryland, Baltimore, MD
*Purpose: Non-alcoholic fatty liver disease (NAFLD) is characterized by metabolic syndrome and the accumulation of fat in the liver cells (hepatocytes) leading to inflammation and…
2021 American Transplant Congress
Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis
C. L. Hanlon¹, B. Saberi², L. Yuan¹
¹Internal Medicine, University of Southern California, Los Angeles, CA, ²Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: This study aims to evaluate regional trends in liver transplantation (LT) among adults in the United States (US) with nonalcoholic steatohepatitis (NASH), with particular…
2021 American Transplant Congress
Excellent Pathological Response with Gemcitabine-based Protocol in Patient with Hilar Cholangiocarcinoma
A. Saharia¹, R. McMillan¹, S. Kodali¹, M. Javley², C. M. Mobley¹, M. J. Hobeika¹, A. Shetty¹, D. W. Victor¹, R. McFadden¹, M. Abdelrahim¹, K. Heyne¹, A. O. Gaber¹, R. M. Ghobrial¹
¹Houston Methodist Hospital, Houston, TX, ²MD Anderson Cancer Center, Houston, TX
*Purpose: The standard treatment for hilar cholangiocarcinoma is using 5FU along with brachytherapy and external beam radiation. The downside of this regimen is the uncertain…